We are live on ! Find out more
RLAY icon

Relay Therapeutics
RLAY

148 hedge funds and large institutions have $2.02B invested in Relay Therapeutics in 2022 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 69 increasing their positions, 23 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 23

79% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 14

6.53% more ownership

Funds ownership: 104.46% → 110.99% (+6.5%)

6% more funds holding

Funds holding: 140 → 148 (+8)

29% less funds holding in top 10

Funds holding in top 10: 7 → 5 (-2)

40% less capital invested

Capital invested by funds: $3.38B → $2.02B (-$1.36B)

Holders
148
Holders Change
+8
Holders Change %
+5.71%
% of All Funds
2.49%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.08%
New
25
Increased
69
Reduced
23
Closed
14
Calls
$5.88M
Puts
–
Net Calls
+$5.88M
Net Calls Change
+$5.68M

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$35.7M
2
State Street
State Street
Massachusetts
+$32.7M
3
EC
EcoR1 Capital
California
+$30.7M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$18.9M
5
ACH
ArrowMark Colorado Holdings
Colorado
+$17.5M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$62.3M
2
DCM
Driehaus Capital Management
Illinois
-$20.5M
3
BI
BVF Inc
California
-$3.12M
4
GGHC
Gilder Gagnon Howe & Co
New York
-$2.99M
5
Citadel Advisors
Citadel Advisors
Florida
-$1.53M
Name Holding Trade Value Shares
Change 		Change in
Stake
RSCM
26
Rock Springs Capital Management
Maryland
$10.4M +$356K +16,600 +3%
Bessemer Group
27
Bessemer Group
New Jersey
$9.79M – – –
CS
28
Candriam SCA
Luxembourg
$9.34M +$3.14M +146,401 +36%
RCM
29
RA Capital Management
Massachusetts
$9.2M – – –
Charles Schwab
30
Charles Schwab
California
$9.14M +$19.2K +894 +0.2%
HMC
31
Harvard Management Company
Massachusetts
$9.06M – – –
NI
32
Nextech Invest
Switzerland
$7.96M – – –
IHAM
33
Integral Health Asset Management
New York
$7.31M +$2.34M +109,262 +33%
ACA
34
Avoro Capital Advisors
New York
$6.7M +$8.57M +400,000 New
Dimensional Fund Advisors
35
Dimensional Fund Advisors
Texas
$6.59M +$7.2M +335,925 +581%
WP
36
Woodline Partners
California
$5.55M – – –
Artisan Partners
37
Artisan Partners
Wisconsin
$5.09M -$3.13K -146 -0%
SC
38
Sessa Capital
New York
$5.04M – – –
Bank of New York Mellon
39
Bank of New York Mellon
New York
$4.99M +$230K +10,730 +4%
HP
40
Harbourvest Partners
Massachusetts
$4.96M – – –
N
41
Nuveen
North Carolina
$4.52M +$1.13M +52,523 +24%
American Century Companies
42
American Century Companies
Missouri
$3.7M +$347K +16,201 +8%
Baillie Gifford & Co
43
Baillie Gifford & Co
United Kingdom
$3.68M -$528K -24,655 -10%
Citigroup
44
Citigroup
New York
$3.12M +$3.32M +154,898 +496%
Millennium Management
45
Millennium Management
New York
$3.11M +$3.68M +171,797 +1,249%
FIM
46
Fernwood Investment Management
Massachusetts
$3.1M – – –
TI
47
Trexquant Investment
Connecticut
$3.07M +$3.93M +183,287 New
Rafferty Asset Management
48
Rafferty Asset Management
New York
$3.05M +$253K +11,824 +7%
GCP
49
GSA Capital Partners
United Kingdom
$2.99M +$3.83M +178,593 New
Schroder Investment Management Group
50
Schroder Investment Management Group
United Kingdom
$2.87M +$1.85M +86,491 +102%
1
2
3 4 5

RLAY Hedge Fund Activity: Q2 2022 in Review

148 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q2 2022, worth a combined $2.02B — down 40% from $3.38B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new RLAY positions and 14 closed out — a net gain of 11 holders — while 69 added to existing stakes and 23 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $35.7M. The largest seller was Fidelity Investments, cutting an estimated $62.3M.

  • 148 institutional investors held Relay Therapeutics (RLAY) as of Q2 2022, up from 140 in Q1 2022.
  • Funds reported $2.02B of Relay Therapeutics stock for Q2 2022, down 40% quarter-over-quarter.
  • 25 funds opened new Relay Therapeutics positions in Q2 2022 and 14 closed out, a net change of +11 holders.
  • The largest Relay Therapeutics buyer in Q2 2022 was JP Morgan Chase, an estimated $35.7M added.
  • The largest Relay Therapeutics seller in Q2 2022 was Fidelity Investments, an estimated $62.3M sold.

Based on aggregated 13F filings for Q2 2022.